Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2020-02-26 Foreign Filer Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2020-02-26 English
6-K
Foreign Filer Report
2020-02-26 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing Classification · 100% confidence The document is a formal notification of transactions in company shares by members of the Board of Directors (Anders Gersel Pedersen, Daniel J. Bruno, and Peter Storm Kristensen). It explicitly references Article 19 of Regulation No. 596/2014 on Market Abuse, which is the standard regulatory framework for reporting insider/director dealings. The content consists of tables detailing the nature of the transaction (sale of shares), price, volume, and date, which is the hallmark of a Director's Dealing (DIRS) filing.
2020-02-26 English
Director's Dealing 2020
Director's Dealing Classification · 100% confidence The document is titled 'Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons' and explicitly states it discloses data of transactions made by managerial employees in accordance with Article 19 of Regulation No. 596/2014 (Market Abuse Regulation). This directly corresponds to the definition of Director's Dealing (insider trades by executives). The presence of an 'Attachment' link suggests this is an announcement, but the core content is the disclosure itself, which is a specific regulatory filing type related to insider transactions, not just a general report publication announcement (RPA). Therefore, the most specific classification is DIRS.
2020-02-26 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing Classification · 98% confidence The document explicitly states it is a 'Company Announcement' disclosing 'data of the transactions made in Genmab A/S by managerial employees and their closely associated persons' in accordance with Article 19 of Regulation No. 596/2014 (Market Abuse Regulation). This regulation mandates the disclosure of insider transactions. The filing category 'Director's Dealing' (DIRS) specifically covers reports of personal share transactions by company directors and executives (insider trades). Although there is an attachment, the primary purpose of this text is the disclosure itself, not just announcing the attachment, making DIRS more specific than RPA or RNS.
2020-02-26 English
6-K
Foreign Filer Report
2020-02-25 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.